Shirin Elizabeth Khorsandi, Suttiruk Jitraruch, Lynette Fairbanks, Corina Cotoi, Wayel Jassem, Hector Vilca‐Melendez, Andreas Prachalias, Anil Dhawan, Nigel Heaton, Parthi Srinivasan – 7 March 2014 – Donation after cardiac death (DCD) livers are considered to be marginal organs for solid organ and cell transplantation. Low energy charge (EC) and low purine quantity within the liver parenchyma has been associated with poor outcome after liver transplantation.

Gui‐lian Xu, Jian Chen, Fei Yang, Gui‐qing Li, Li‐xin Zheng, Yu‐zhang Wu – 7 March 2014 – Viral fulminant hepatitis (FH) remains a serious clinical problem with very high mortality. Lacking understanding of FH pathogenesis has in essence hindered efficient clinical treatment. Inferring from a correlation observed between the genetic differences in the complement component 5 (C5) and the susceptibility of mouse strains to murine hepatitis virus strain‐3 (MHV‐3) infections, we propose that excessive complement activation plays a critical role in the development of FH.

Simon W. Beaven – 7 March 2014

Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Akio Ido, Kazuhide Yamamoto, Koichi Takaguchi, Namiki Izumi, Kazuhiko Koike, Tetsuo Takehara, Norifumi Kawada, Michio Sata, Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Andrew Damokosh, Hiroki Ishikawa, Eric Hughes – 6 March 2014 – All‐oral combinations of direct‐acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin‐based regimens.

Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Akio Ido, Kazuhide Yamamoto, Koichi Takaguchi, Namiki Izumi, Kazuhiko Koike, Tetsuo Takehara, Norifumi Kawada, Michio Sata, Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Andrew Damokosh, Hiroki Ishikawa, Eric Hughes – 6 March 2014 – All‐oral combinations of direct‐acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates for current interferon/ribavirin‐based regimens.

Jamuna Karkhanis, Elizabeth C. Verna, Matthew S. Chang, R. Todd Stravitz, Michael L. Schilsky, William M. Lee, Robert S. Brown – 5 March 2014

Stephen A. Geller – 5 March 2014

Albert Parés – 5 March 2014

John M. Vierling – 5 March 2014 – Watch a video presentation of this article

Christopher L. Bowlus – 5 March 2014 – Watch a video presentation of this article